January 11, 2022 – A growing body of research suggests that early-life infection, inflammation, and metabolic changes could contribute to psychiatric disorders – perhaps via effects during critical periods of brain development. New evidence on how "immunometabolic" risk factors in childhood may affect the development of depression and psychotic disorders in adulthood is presented in the January/February special issue of Harvard Review of Psychiatry. The journal is published in the Lippincott portfolio by Wolters Kluwer.
If confirmed, this line of research might lead to new approaches to treating depression and psychosis in adults – and possibly efforts to prevent these disorders by targeting early-life immunometabolic risk factors in childhood, according to the report by Nils Kappelmann, PhD, of Max-Planck-Institute of Psychiatry, Munich, and colleagues. The study is one of seven special issue papers exploring possible links between inflammation and mental health disorders.
Complex connections between early-life stress, inflammation, and brain development
Previous research has suggested that maternal and childhood infections may be related to the later development of psychiatric diagnoses – particularly psychotic disorders such as schizophrenia. Other studies have linked markers of inflammation during childhood and adolescence to increased rates of depression and psychosis in adulthood. However, these associations appear highly complex, with specific inflammatory markers linked to later development of specific types of symptoms.
Research has also suggested links between metabolic alterations and psychiatric disorders. In particular, increased body mass index (BMI) and body fat seem to be associated with an increased risk of depression, while lower BMI may be linked to increased risk of psychotic disorders. Other studies suggest that young people with disrupted glucose-insulin balance may be at increased risk of later psychosis, whereas depression may lead to later glucose-insulin dysregulation.
Inflammatory and metabolic changes might interact with other factors affecting the development of psychiatric disorders – particularly genetic predispositions and adverse experiences or maltreatment during early life. "Together, these findings suggest that higher levels of infection, inflammation, and metabolic alterations commonly seen in people with depression and psychosis could be a cause for, rather than simply a consequence of, these disorders," Dr. Kappelmann and coauthors write.
They call for innovative research approaches to evaluate the causal nature and mechanisms of these associations. "Interventional studies are also needed to test the potential usefulness of targeting early-life immuno-metabolic alterations for preventing adult depression and psychosis," the researchers add. Some groups of patients might benefit from treatment with anti-inflammatory drugs – although so far, clinical trials of this approach have yielded mixed results.
"This special issue of the Harvard Review of Psychiatry tackles this intriguing topic of psychoimmunology from various perspectives reflecting the interdisciplinary nature of the problem at hand," according to an introduction by guest editor Paulo Lizano, MD, PhD, of Harvard Medical School and Beth Israel Deaconess Medical Center. The topics "summarize the complexity of the inflammatory-brain connection while establishing that inflammation can be causal in a subset of psychiatric disorders and does not follow categorization outlined in the Diagnostic and Statistical Manual of Mental Disorders."
Dr. Lizano adds, "Despite these many advances, much still remains unknown, and further research is needed to enhance the clinical applicability of these findings." Key topics for future research include identifying different "inflammatory subtypes" of psychiatric disorders to help in developing specific treatment strategies, and potentially using early recognition and treatment to prevent low-grade brain inflammation during development.
About the Harvard Review of Psychiatry
The Harvard Review of Psychiatry is the authoritative source for scholarly reviews and perspectives on a diverse range of important topics in psychiatry. Founded by the Harvard Medical School Department of Psychiatry, the journal is peer reviewed and not industry sponsored. It is the property of Harvard University and is affiliated with all of the Departments of Psychiatry at the Harvard teaching hospitals. Articles encompass major issues in contemporary psychiatry, including neuroscience, epidemiology, psychopharmacology, psychotherapy, history of psychiatry, and ethics.
About Wolters Kluwer
Wolters Kluwer (WKL) is a global leader in professional information, software solutions, and services for the clinicians, nurses, accountants, lawyers, and tax, finance, audit, risk, compliance, and regulatory sectors. We help our customers make critical decisions every day by providing expert solutions that combine deep domain knowledge with advanced technology and services.
Wolters Kluwer reported 2020 annual revenues of €4.6 billion. The group serves customers in over 180 countries, maintains operations in over 40 countries, and employs approximately 19,200 people worldwide. The company is headquartered in Alphen aan den Rijn, the Netherlands.
Wolters Kluwer provides trusted clinical technology and evidence-based solutions that engage clinicians, patients, researchers and students in effective decision-making and outcomes across healthcare. We support clinical effectiveness, learning and research, clinical surveillance and compliance, as well as data solutions. For more information about our solutions, visit https://www.wolterskluwer.com/en/health and follow us on LinkedIn and Twitter @WKHealth.
Harvard Review of Psychiatry